Welcome to our dedicated page for Sotera Health Co SEC filings (Ticker: SHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Sotera Health Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Sotera Health Co's regulatory disclosures and financial reporting.
Chen Ruoxi reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co director Ruoxi Chen received an equity grant of 14,970 Restricted Stock Units (RSUs) on May 22, 2026. The RSUs were granted at no cash cost as part of the Sotera Health Company 2020 Omnibus Incentive Plan and represent the right to receive an equal number of common shares, subject to vesting conditions.
The RSUs will vest in full on the earlier of the first anniversary of the grant date or immediately before the next regular annual shareholders meeting, assuming Chen continues serving as a non-employee director. Following this award, Chen holds 95,751 securities in total, consisting of 14,970 RSUs and 80,961 shares of common stock.
Sotera Health Co director Christopher Simon received a grant of 14,970 restricted stock units (RSUs) of Common Stock on May 22, 2026 as compensation. Each RSU converts into one share of Common Stock if vesting conditions are met. The RSUs vest in full on the earlier of the first anniversary of the grant date or immediately before the next regular annual shareholders meeting, assuming he continues to serve as a non-employee director. After this award, Simon holds 34,102 equity interests in total, consisting of 14,970 RSUs and 19,132 shares of Common Stock held directly.
Wheadon David E. reported acquisition or exercise transactions in this Form 4 filing.
Sotera Health Co director David E. Wheadon received an equity grant of 14,970 restricted stock units (RSUs). The RSUs were awarded at no cash cost under the Sotera Health Company 2020 Omnibus Incentive Plan, as part of his compensation for serving as a non-employee director.
Each RSU represents the right to receive one share of common stock, subject to vesting. The grant vests in full on the earlier of the first anniversary of the grant date or immediately before the company’s next regular annual shareholders meeting, if he remains a director. Following this grant, he holds 89,882 shares and RSUs in total, consisting of 14,970 RSUs and 74,912 shares of common stock.
Sotera Health Company reported the results of its 2026 annual meeting of stockholders held on May 21, 2026. Stockholders elected four Class III directors to three-year terms ending at the 2029 annual meeting and continuing until their successors are elected and qualified.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers. In addition, they ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Sotera Health Company entered into Amendment No. 7 to its First Lien Credit Agreement, under which 2026 Refinancing Term Lenders will provide term loans to Sotera Health Holdings, LLC in an aggregate principal amount of $1,415,914,725.62. The amendment mainly reprices existing debt by reducing the interest rate spread by 0.25% across term loans under the facility.
The repriced term loans will bear interest at Adjusted Term SOFR plus 2.25%, with an option to elect Alternate Base Rate plus 1.25% or Adjusted Daily Simple SOFR plus 2.25%. The loans carry a 1.00% soft call premium for certain repricing transactions within six months of the amendment’s effective date, amortize at 1.00% per year, and mature on May 30, 2031.
Warburg Pincus entities file an exit Schedule 13G/A for Sotera Health Co. As of May 13, 2026, the Warburg Pincus Reporting Persons state they no longer own any shares of Common Stock of Sotera Health Co; the filing is described as an exit filing.
The amendment lists the group members and their relationships and incorporates a joint filing agreement as Exhibit 99.1.
Sotera Health Co disclosed that investment entities affiliated with Warburg Pincus sold 19,102,952 shares of Common Stock of Sotera Health in an underwritten public secondary offering on May 13, 2026 at $15.168 per share.
After this transaction, the reporting Warburg Pincus entities reported zero shares of Sotera Health common stock in this filing and describe themselves collectively as the Warburg Pincus Entities, which may hold pecuniary interests through a complex partnership structure.
Sotera Health Co large shareholder entities affiliated with Warburg Pincus reported a major disposition of Common Stock. On May 13, 2026, certain Warburg Pincus Entities sold 19,102,952 shares of Sotera Health common stock in an underwritten public secondary offering. The reported indirect holdings for this line item fell to 0 shares following the transaction, and the entities disclaim beneficial ownership beyond any pecuniary interest.
Sotera Health Co disclosed that investment funds affiliated with GTCR sold 12,735,301 shares of Common Stock in an underwritten public secondary offering at $15.168 per share. These shares were held indirectly through GTCR XI funds and related entities.
Following this transaction, the reporting GTCR entities report zero shares of Sotera Health Common Stock held. The GTCR entities are described as directors-by-deputization for Section 16 purposes, and individual members of the GTCR board of managers disclaim beneficial ownership except for any pecuniary interest.
GTCR Reporting Persons exit Sotera Health Co. This Amendment No. 7 states that, as of May 13, 2026, the GTCR Reporting Persons no longer beneficially own any shares of Sotera Health Co. common stock (CUSIP 83601L102). The filing is an exit/amendment under Rule 13d-1(k) and attaches a joint filing agreement as Exhibit 99.1.